Enhancing ADC Translatability by Developing Advanced Tumour Resistance Models
- Development of predictive preclinical resistance models
- Mechanistic insights into intrinsic and acquired resistance pathways
- Biomarker-driven strategies for patient selection to improve the clinical translatability of ADC therapies